b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30976993</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>02</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>09</Day>\n        </DateRevised>\n        <Article PubModel="Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1550-7416</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>21</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>04</Month>\n                        <Day>11</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>The AAPS journal</Title>\n                <ISOAbbreviation>AAPS J</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXa<sup>I16L</sup> in Preclinical Species.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>52</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1208/s12248-019-0324-z</ELocationID>\n            <Abstract>\n                <AbstractText>This paper presents a systemic investigation of ADA development and ADA impact of a human coagulation factor in nonclinical species during drug development and provides insights into potential implications in human if a similar ADA occurs. FXa<sup>I16L</sup>-induced ADA response was characterized in monkey, mouse, rat, and dog in different studies, and ADA effects on pharmacokinetic and/or pharmacodynamics of FXa<sup>I16L</sup> were further examined in ADA-negative and ADA-positive animals. After repeated administrations, FXa<sup>I16L</sup> elicited a dose and exposure day-dependent ADA response which ranged from no response to a transient or persistent response. Increase in exposure day and increase in dose generally enhanced ADA incidence except for a decrease in ADA incidence was observed in monkeys after repeated high-dose administrations. The observable ADA impact on pharmacokinetics was only found in some ADA+ animals and included decrease in clearance and increase in systemic exposure but no increase in half-life. In addition, no or limited effect on pharmacodynamics by ADA was observed. The earliest ADA response was observed after three exposure days, marked elevation of drug exposure was observed in some animals at log titer &gt;\xe2\x80\x892.0, and the highest antibody titer excited was about 4 (Log10) in all species. A correlation between ADA induction and accumulative exposure after various repeat treatments in different species was found for FXa<sup>I16L</sup>. In addition, potential immunogenicity risk and mitigation of ADA in clinics are discussed.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Parng</LastName>\n                    <ForeName>Chuenlei</ForeName>\n                    <Initials>C</Initials>\n                    <Identifier Source="ORCID">0000-0003-2986-5393</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Pfizer Biomedicine Design, Pharmacokinetics Pharmacodynamics Metabolism, 610 Main St., Cambridge, Massachusetts, 02139, USA. chuenlei.parng@pfizer.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bolt</LastName>\n                    <ForeName>Michael</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pfizer Drug Safety Research and Development, Cambridge, Massachusetts, 02139, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pittman</LastName>\n                    <ForeName>Debra D</ForeName>\n                    <Initials>DD</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pfizer Rare Disease Research Unit, Cambridge, Massachusetts, 02139, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Caiazzo</LastName>\n                    <ForeName>Teresa</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pfizer Biomedicine Design, Andover, Massachusetts, 01810, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dyleski</LastName>\n                    <ForeName>Lisa</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pfizer Biomedicine Design, Andover, Massachusetts, 01810, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gorovits</LastName>\n                    <ForeName>Boris</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pfizer Biomedicine Design, Andover, Massachusetts, 01810, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Webster</LastName>\n                    <ForeName>Rob</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pfizer Biomedicine Design, Pharmacokinetics Pharmacodynamics Metabolism, 610 Main St., Cambridge, Massachusetts, 02139, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>04</Month>\n                <Day>11</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>AAPS J</MedlineTA>\n            <NlmUniqueID>101223209</NlmUniqueID>\n            <ISSNLinking>1550-7416</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.4.21.6</RegistryNumber>\n                <NameOfSubstance UI="D015951">Factor Xa</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001777" MajorTopicYN="N">Blood Coagulation</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015951" MajorTopicYN="N">Factor Xa</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006467" MajorTopicYN="N">Hemophilia A</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010314" MajorTopicYN="N">Partial Thromboplastin Time</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011517" MajorTopicYN="N">Prothrombin Time</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">FXaI16L</Keyword>\n            <Keyword MajorTopicYN="Y">anti-drug antibody</Keyword>\n            <Keyword MajorTopicYN="Y">coagulation factor</Keyword>\n            <Keyword MajorTopicYN="Y">exposure day</Keyword>\n            <Keyword MajorTopicYN="Y">hemophilia inhibitor</Keyword>\n            <Keyword MajorTopicYN="Y">neutralizing antibody</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>02</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>22</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>13</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>13</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30976993</ArticleId>\n            <ArticleId IdType="doi">10.1208/s12248-019-0324-z</ArticleId>\n            <ArticleId IdType="pii">10.1208/s12248-019-0324-z</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Haemophilia. 2011 Jan;17(1):e172-82</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20609014</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Haemophilia. 2010 Mar;16(2):256-62</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19878331</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Thromb Haemost. 2017 May;15(5):931-937</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28294526</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Pharm Sci. 2017 Aug;106(8):2136-2143</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28389265</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):657-662</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27913543</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet. 2003 Oct 11;362(9391):1184-91</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">14568740</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Rev Immunol. 2015 Mar;15(3):185-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25677493</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Trends Immunol. 2007 Nov;28(11):482-90</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17964218</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Immunol Methods. 2008 Apr 20;333(1-2):1-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18275969</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Interferon Cytokine Res. 2002 Feb;22(2):207-13</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11911803</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Thromb Haemost. 2012 Oct;10(10):2194-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22846047</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood. 2011 Jan 6;117(1):290-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20864578</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ther Adv Drug Saf. 2011 Jun;2(3):113-28</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25083207</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Biol Chem. 2008 Jul 4;283(27):18627-35</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18460471</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Blood. 2007 Jun 1;109(11):4648-54</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17289808</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'